Masters Capital Management LLC boosted its position in shares of Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS – Free Report) by 100.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 500,000 shares of the company’s stock after purchasing an additional 250,002 shares during the quarter. Masters Capital Management LLC’s holdings in Senseonics Holdings, Inc. Common Stock were worth $3,330,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Jain Global LLC purchased a new stake in shares of Senseonics Holdings, Inc. Common Stock in the 4th quarter worth $88,000. State of Wyoming increased its stake in shares of Senseonics Holdings, Inc. Common Stock by 202.6% during the second quarter. State of Wyoming now owns 182,989 shares of the company’s stock valued at $87,000 after buying an additional 122,510 shares during the period. Hudson Bay Capital Management LP bought a new stake in shares of Senseonics Holdings, Inc. Common Stock in the fourth quarter valued at about $85,000. Beck Mack & Oliver LLC raised its holdings in shares of Senseonics Holdings, Inc. Common Stock by 16.5% in the second quarter. Beck Mack & Oliver LLC now owns 176,950 shares of the company’s stock valued at $84,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Captrust Financial Advisors purchased a new stake in Senseonics Holdings, Inc. Common Stock in the fourth quarter worth about $77,000. 12.36% of the stock is owned by institutional investors.
Senseonics Holdings, Inc. Common Stock Stock Performance
SENS opened at $4.86 on Monday. The company has a current ratio of 3.51, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. The company has a market cap of $203.15 million, a price-to-earnings ratio of -2.43 and a beta of 0.99. Senseonics Holdings, Inc. Common Stock has a 12 month low of $4.79 and a 12 month high of $11.60. The stock has a fifty day moving average of $6.03.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on the stock. Mizuho dropped their target price on shares of Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Weiss Ratings lowered shares of Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. HC Wainwright lowered their price target on shares of Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Finally, Stifel Nicolaus dropped their price objective on shares of Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating on the stock in a research note on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Senseonics Holdings, Inc. Common Stock has an average rating of “Moderate Buy” and an average price target of $17.20.
Get Our Latest Analysis on SENS
Insider Buying and Selling
In other news, Director Douglas A. Roeder purchased 22,686 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was acquired at an average cost of $5.56 per share, with a total value of $126,134.16. Following the completion of the transaction, the director owned 144,635 shares in the company, valued at $804,170.60. This represents a 18.60% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.70% of the company’s stock.
About Senseonics Holdings, Inc. Common Stock
Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.
Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.
Further Reading
- Five stocks we like better than Senseonics Holdings, Inc. Common Stock
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Want to see what other hedge funds are holding SENS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS – Free Report).
Receive News & Ratings for Senseonics Holdings Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
